2015 Fiscal Year Final Research Report
Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
| Project/Area Number |
25462599
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Iwasaki Masahiro 札幌医科大学, 医学部, 准教授 (20516504)
Tanaka Ryoichi 札幌医科大学, 医学部, 講師 (60448602)
Sato Noriyuki 札幌医科大学, その他, 名誉教授 (50158937)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 免疫療法 / 子宮頸癌 / HPV / ワクチン |
|---|
| Outline of Final Research Achievements |
The aim of this study was to establish an efficient HPV type 16-targeting cancer immunotherapy. HPV16-derived viral proteins E6 and E7 are expressed in cancerous cells through the progression of the disease and have a role in carcinogenesis but are not expressed in normal cells. In this study, we generated a novel HPV 16 E6 and E7 gene plasmid containing oligomannose liposomes (OML-HPV). We compared the cytotoxic T lymphocyte (CTL) induction efficiency of OML-HPV and that of standard liposome-HPV16 E6 and E7 DNA complex. HPV16 E6-specific CTLs could be generated from HPV 16-positive cervical carcinoma patient's peripheral blood mononuclear cells by stimulating OML-HPV, but could not by stimulating standard liposome-HPV 16 E6, E7 DNA complex. These results indicate that OML-HPV is a more effective approach than DNA vaccination using standard liposomes, and that a novel HLA-A24-restricted peptide, E6 66-74, might be a suitable target of cervical cancer immunotherapy.
|
| Free Research Field |
婦人科腫瘍
|
